QuickLinks -- Click here to rapidly navigate through this document
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 12, 2004
CUBIST PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
Delaware
(State or Other Jurisdiction
of Incorporation) | | 0-21379
(Commission
File Number) | | 22-3192085
(IRS Employer
Identification No.) |
65 Hayden Avenue, Lexington, Massachusetts 02421
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (781) 860-8660
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
- o
- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o
- Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))
- o
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- o
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
On November 12, 2004 Scott M. Rocklage, Ph.D., the Chairman of the registrant's Board of Directors, announced that he is retiring as Chairman and resigning from the registrant's Board of Directors to be effective as of December 31, 2004.
Item 8.01 Other Events.
On November 12, 2004, the registrant issued a press release relating to the announcement by Scott M. Rocklage, Ph.D., the Chairman of the registrant's Board of Directors, that he is retiring as Chairman and resigning from the registrant's Board of Directors to be effective as of December 31, 2004.
Item 9.01 Financial Statements and Exhibits.
99.1 |
|
Press Release dated November 12, 2004 |
The attached press release shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | CUBIST PHARMACEUTICALS, INC. |
|
|
By: |
|
/s/ DAVID W. J. MCGIRR
David W. J. McGirr
Senior Vice President and Chief Financial Officer |
Dated: November 12, 2004 |
|
|
|
|
2
QuickLinks
SIGNATURES
